Table 2.
Schemes of delivered neoadjuvant treatments according to axillary clinical stage at diagnosis and related clinical response.
| cN0 | cN1/2 | |
|---|---|---|
| All | 219 (54.8%) | 180 (45.2%) |
| Neoadjuvant treatment | ||
| Hormone Therapy | 23 (10.5%) | 1 (0.6%) |
| Chemotherapy | 196 (89.5%) | 179 (99.4%) |
| Neoadjuvant chemotherapy | ||
| Anthracycline and/or Taxane | 5 (2.6%) | 4 (2.2%) |
| Anthracycline + Taxane | 159 (81%) | 141 (78.8%) |
| Other | 32 (16.4%) | 34 (19%) |
| Herceptin containing regimen | 64 (29.2%) | 59 (32.8%) |
| Clinical response | ||
| Complete response | 77 (35.2%) | 67 (37.2%) |
| Partial response | 125 (57%) | 103 (57.3%) |
| No response | 8 (3.7%) | 4 (2.2%) |
| Progression | 9 (4.1%) | 6 (3.3%) |